ArticleCardio-oncology (London, England)2026
SWATH-MS for discovery of early biomarkers of drug-induced cardiotoxicity using an animal doxorubicin model.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundClinical use of anthracyclines is limited by cumulative dose-dependent cardiotoxicity, though the mechanisms responsible for this are complex and incompletely understood. Existing biomarkers of anthracycline-related cardiotoxicity, such as troponin and NT-proBNP, lack sensitivity for the earliest stages of cardiotoxicity, therefore limiting scope to switch to alternative, safer treatment. As such, a reliable early biomarker of anthracycline-related cardiotoxicity remains a key unmet research need.
methodsWe investigated the rat myocardial proteome to identify novel biomarkers of anthracycline-related cardiotoxicity warranting further investigation for routine clinical application. Six groups of 8 Han-Wistar rats were dosed weekly for 1-7 doses with either doxorubicin 1.25 mg/kg or saline control, followed by terminal bleeds. Sequential window acquisition of all theoretical mass spectra (SWATH-MS) was used to compare the rat myocardial proteome at serial timepoints and between doxorubicin- and saline-treated animals. A shortlist of candidate biomarkers was generated by identifying proteins with significant log
resultsThree proteins were differentially expressed at early, mid- and late timepoints (myosin light chain 3, desmin and cysteine-rich protein 2). A further 10 proteins were differentially expressed at mid- and late timepoints. Pathway analysis identified biological processes enriched within the myocardial proteome, predominantly related to muscle, metal ion, haemostasis, lipid and inflammation processes. A candidate biomarker shortlist of 34 proteins was derived for future study.
conclusionWe used a rat anthracycline dosing schedule to recapitulate the development of cardiotoxicity observed in humans. We describe a shortlist of 34 proteins with promise as candidate biomarkers of the earliest stages of anthracycline-related cardiotoxicity and summarise pathway analysis of functionally enriched biological processes within the rat myocardial proteome during anthracycline treatment. Further study is underway to explore these shortlisted proteins in rat plasma, with a human study planned to validate best-performing biomarkers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.